Patients undergoing transcatheter atrial septal defect (ASD) closure did not have worsening migraines after completing a course of dual antiplatelet therapy, the CANOA investigators found. Overall, ...
Three months of clopidogrel is sufficient to curb new-onset migraine headaches after percutaneous atrial septal defect (ASD) closure, new data from the randomized CANOA trial show. There was no ...
Patients being treated with dual-antiplatelet therapy (DAPT) consisting of clopidogrel plus aspirin following atrial septal defect (ASD) closure can safely discontinue clopidogrel after 3 months ...
Atrial septal defect closure techniques have evolved considerably over recent decades. Traditional surgical repair, once the mainstay of treatment for congenital heart anomalies, has gradually been ...
Initial data looking at safety and efficacy of an interatrial septal occluder with a bioresorbable frame show promise for closing atrial septal defects (ASDs), but the study authors suggest a redesign ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results